Strontium 89 in the treatment of pain due to diffuse osseous metastases: A university hospital experience

Journal of the National Medical Association

Volumn 94, Issue 8, 2002, Pages 706-711

  Ashayeri, Ebrahim ^a   Omogbehin, Adedamola ^a   Sridhar, Rajagopalan ^a   Shankar, Ravi A ^a  

^a HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

Bone pain; Palliative therapy; Strontium 89

Indexed keywords

STRONTIUM; STRONTIUM CHLORIDE;

AFRICAN AMERICAN; ARTICLE; BONE TUMOR; BREAST TUMOR; FEMALE; HUMAN; MALE; METASTASIS; PAIN; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

AFRICAN AMERICANS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STRONTIUM; STRONTIUM RADIOISOTOPES;

EID: 0036672911     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ben-Josef E, Shamsa F, Williams AO. Radiotherapuetic management of osseous metastasis: a survey of current patterns of care. Int J Radial Oncol Biol Phys. 1998, March 1;40:915-921.
2. Serafini AN, Houston SJ, Resche I. Palliation of pain associated with metastatic bone cancer using Samarium-153 Lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998 April;16:1574-1581.
3. Menda Y, Bushnell DL, Williams RD. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med. 2000 Sept.;25:698-700.
4. Friedland, J. Local and systemic radiation for palliation of metastatic disease: Urol Clin North Am. 1999 May, 26:391-402.
5. Levy MH. Pain control in patients with cancer. Oncology (Hunting). 1999 May; 13(5 Suppl 2):9-14.
6. Quilty PM, Kirk D, Bolger JJ. A comparison of the palliative effects of strontium-89 and external beam radiation therapy in metastatic prostate cancer. Radiother Oncol. 1994 April;31: 33-40.
7. Salazar OM, Rubin P, Hendrickson FR. Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Cancer. 1986 July 1;58:29-36.
8. Friedell HL, Storaasli JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread bony metastases to bone. Am J Roentgen. 1950;64:559-575.
9. Walsh JS, Thurman ST. Samarium-153 plus external beam radiation therapy in bone metastasis. Case studies in Oncol, Physicians Education Resource, Baylor Charles A. Sammons Cancer Center, Dallas, TX. Vol. 2 no. 5, June 2000.
10. Porter AT, McEwan AJ, Powe JE. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic cancer. Int J Radiat Oncol Biol Phys. 1993 April 2;25:805-813.
11. Laing AH, Ackery DM, Bayly RJ. Strontium 89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991 Sept.;64:816-822.
12. Mertens WC, Porter AT, Reid RH. Strontium 89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med. 1992 Aug.;33:1437-1443.
13. Sciuto R, Maini CL, Tofani A. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with Strontium 89. Nucl Med Commun. 1996 Sept.;17:799-804.
14. Blake GM, Zivanovic MA, McEvan AJ. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986;12:447-454.
15. Silberstein EB, Eugene L, Saenger SR. Painful osteoblastic metastases: the role of nuclear medicine. Oncology (Hunting). 2001 Feb.;15:157-163; discussion 167-170, 174.
16. Harrington KD. The management of acetabular insufficiency secondary to metastatic malignant disease. J Bone Joint Surg. 1981;54:653.
17. Higinbotham NL, and Marcove RC. The management of pathologic fractures. J Trauma. 1965;5:792.
18. Body JJ: Metastatic bone disease: Clinical and therapeutic aspects. Bone 1992;13:557-562.
19. th ed., Lippincott Williams & Wilkins, Philadelphia, PA , 2001, p. 2713-2729.
20. rd, Payne R. The management of intractable bone pain: a clinician's perspective. Semin Nucl Med. 1992;22:3-10.
21. Cherny NI. The management of cancer pain. CA Cancer J Clin. 2000;50:70-120.
22. Serafini AN. Palliation of metastases associated bone pain with Samarium-153 Lexidronam. Case studies in Oncology, Nov. 2000, vol.2, no. 9, pgs.1-7.
23. Friedland J. Local and systemic radiation for palliation of metastatic disease. Urol Clin North Am. 1999;26:391-402.
24. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 Lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
25. Porter AT, Ben-Josef E, Davis L. Systemic administration of new therapeutic radioisotopes, including phosphorus, strontium, samarium and rhenium. Curr Opin Oncol 1994;6:607-610.
26. Brawley OW. Prostate cancer and black men. Semin Urol Oncol. 1998 Nov;16:184-186.
27. Alexander GA, Brawley OW. Prostate cancer treatment outcome in blacks and whites: a summary of the literature. Semin Urol Oncol. 1998 Nov;16:232-234.
28. Brawley OW, Barnes S. The epidemiology of prostate cancer in the United States. Semin Oncol Nurs. 2001 May; 17:72-77.
29. Chu KC, Tarone RE, Brawley OW. Breast cancer trends of black women compared with white women. Arch Fam Med. 1999 Nov.-Dec.;8:521-528.
30. McEwan AJ, Amyotte GA, McGowan DG et al. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur Urol. 1994;26 Suppl 1:26-31.